What is it about?
In simple terms, lung scarring in patients with rheumatoid arthritis can be significantly slowed by the use of a class of drugs called anti-fibrotics. These agents can be combined with other drugs given to try and reverse or at least stabilise lung inflammation
Featured Image
Why is it important?
We critical review an original paper describing the real life application of this treatment in 65 patients with rheumatoid arthritis related interstitial lung disease and indicate what has been learned - and what more needs to be done
Perspectives
This is a useful foundation to the upcoming guidelines which we are helping to jointly produce between the BSR and BTS to allow consensus in this evolving area of front line therapeutics.
Clive Kelly
James Cook university hospital, Middlesbrough
Read the Original
This page is a summary of: Practical Issues Relating to the Use of Antifibrotic Therapy in Patients With Interstitial Lung Disease and Rheumatoid Arthritis, The Journal of Rheumatology, April 2025, The Journal of Rheumatology,
DOI: 10.3899/jrheum.2025-0103.
You can read the full text:
Contributors
The following have contributed to this page
